Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A single-cell survey of cellular hierarchy in acute myeloid leukemia

ABSTRACT: A single-cell survey of cellular hierarchy in acute myeloid leukemia

PROVIDER: PRJNA541288 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR10326542_1.fastq.gz	Fastqsanger.gz
	SRR10326542_2.fastq.gz	Fastqsanger.gz
	SRR10326543_1.fastq.gz	Fastqsanger.gz
	SRR10326543_2.fastq.gz	Fastqsanger.gz
	SRR10326544_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 98

Similar Datasets

The cellular hierarchy of acute myeloid leukemia informs personalized treatment

Project description:The cellular hierarchy of acute myeloid leukemia informs personalized treatment

| PRJNA1137956 | ENA

The cellular hierarchy of acute myeloid leukemia informs personalized treatment

Project description:Acute myeloid leukemia (AML) is characterized by malignant myeloid precursors that span a cellular hierarchy from dedifferentiated leukemic stem cells to mature blasts. While the diagnostic and prognostic importance of AML blast maturation is increasingly recognized, personalized therapies are currently not tailored to a patient’s individual makeup of this cellular hierarchy. In this study, we use multiplexed image-based ex vivo drug screening (pharmacoscopy) to systematically quantify the drug sensitivity across the cellular hierarchy of AML patients. We analyzed 174 prospective and longitudinal patient samples from 44 newly diagnosed AML patients, which indicated that differences in the AML hierarchy significantly identified poor responses to first-line therapy, outperforming European LeukemiaNet (ELN) criteria. Critically, drug response profiling across the AML hierarchy of each patient improved the accuracy of predicting patient response to first-line therapy (AUC 0.91), and revealed alternative individualized treatment options targeting the complete AML hierarchy of non-responding patients. We confirmed these findings in an independent cohort of 26 relapsed/refractory AML patients, for whom pan-hierarchy response profiling improved response predictions post hoc. Overall, our results quantify the clinical importance of therapeutically targeting the complete cellular hierarchy of newly diagnosed AML, and identify multiplexed image-based ex vivo drug screening to enable quantification and targeting of the AML maturation hierarchy for improved personalized treatment.

2024-07-20 | GSE272681 | GEO

A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia

Project description:A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia

| PRJNA820009 | ENA

A single-cell survey of cellular hierarchy in acute myeloid leukemia.

Project description: Not available

| S-EPMC7517826 | biostudies-literature

Myeloid Leukemia

Project description:Myeloid Leukemia

| PRJNA941283 | ENA

A single-cell survey of cellular hierarchy in acute myeloid leukemia

Project description:We applied Micro-well seq, a high-throughput and low-costing single-cell RNA platform, to 40 patients with 3 healthy donors. We identified a key subgroup and characterized its gene expression pattern from diagnosis to relapse, revealing its features in refractory patients. In addition, we combined next generation and SMRT sequencing to track the clonal evolution.

2020-10-06 | GSE130756 | GEO

Investigation of LARP1 regulated cellular pathways in acute myeloid leukemia

Project description:Investigation of LARP1 regulated cellular pathways in acute myeloid leukemia

| PRJNA1300482 | ENA

Transcription profiling of human MLL-AF10 myeloid leukemia cellular subsets

Project description:Leukemia cells from mice with MLL-AF10 AML were fractionated into separate sub-populations on the basis of c-kit expression, which correlates with MLL LSC frequency (Somervaille and Cleary, 2006). The sorted AML sub-populations exhibited substantial differences in their frequencies of AML CFCs/LSCs (mean 14-fold) and morphologic features, consistent with a leukemia cell hierarchy with maturation through to terminally differentiated neutrophils. Experiment Overall Design: Leukemic splenocytes from four mice with MLL-AF10 AML were sub-fractionated in to c-kit high and c-kit negative sub-populations by FACS.

2009-02-21 | E-GEOD-13692 | biostudies-arrayexpress

Ontogenic changes in hematopoietic hierarchy determine pediatric specificity and disease phenotype in fusion oncogene-driven myeloid leukemia - scRNAseq - 2

Project description:Paediatric cancers present specific genetic alterations, however the principles underlying their differences to adult cancers are yet unclear. Poor prognosis paediatric myeloid leukaemia fusion oncogenes represent clinically-relevant models to investigate age-specific tumorigenesis. Here, we established an inducible murine model to show that the ETO2-GLIS2 fusion induces both megakaryoblastic and myeloid leukaemia in a cellular and developmental stage-dependent manner, reproducing different age and phenotype associations observed in patients. The aggressive megakaryoblastic leukemia phenotype developed from haematopoietic stem cells and was associated with massive rewiring of master transcription factors activities (e.g. ERG, GATA and CEBPA). Switching off ETO2-GLIS2 expression in transformed cells restored some long-term haematopoietic stem cell potential. In contrast, targeting downstream progenitors was required for the myeloid phenotype. These data demonstrate that the promiscuity between HSC and megakaryocytic states and the ontogenic changes in the cellular architecture of the hematopoietic tissue controls paediatric and phenotype specificities in myeloid leukaemia.

2019-10-15 | E-MTAB-8360 | biostudies-arrayexpress

Hematopoietic differentiation is required for initiation of acute myeloid leukemia [ATAC-seq]

Project description:Leukemia initiating cells (LICs) of acute myeloid leukemia (AML) may arise from self-renewing hematopoietic stem cells (HSCs) and from committed progenitors. However, it remains unclear how leukemia-associated oncogenes instruct LIC formation from cells of different origins and if differentiation along the normal hematopoietic hierarchy is involved. Here, using murine models with the driver mutations MLL-AF9 or MOZ-TIF2, we found that regardless of the transformed cell types, myelomonocytic differentiation to the granulocyte macrophage progenitor (GMP) stage is critical for LIC generation. Blocking myeloid differentiation through disrupting the lineage-restricted transcription factor C/EBPa eliminates GMPs, blocks normal granulopoiesis, and prevents AML development. In contrast, restoring myeloid differentiation through inflammatory cytokines “rescues” AML transformation. Our findings identify myeloid differentiation as a critical step in LIC formation and AML development, thus guiding new therapeutic approaches. Examination of chromatin accessibility in Cebpa knock-out and control conditions.

2015-08-04 | E-GEOD-71688 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data